
MD| IM resident| @accintouch IM program| Aspiring 🫀
- Tweets14.4K
- Following1.7K
- Followers665
- Likes4.8K

ALT This image contains a slide presentation about the SYNCHRONIZE-CVOT study. The study focuses on cardiovascular outcomes with Survodutide in adults with obesity at increased cardiovascular risk. Objectives, design, and conclusions of the study are summarized. An American Heart Association logo appears in the lower-left corner.

ALT A graph from the Original Article "Intensive Blood-Pressure Lowering in Patients with Type 2 Diabetes.” The trial name, OPTIMAL-DIABETES, is in parentheses after the title. The graph shows Kaplan–Meier curves for the primary outcome. The trial results are being presented at the American Heart Association Scientific Sessions 2026. The logo of the New England Journal of Medicine is at the bottom.

ALT A graph from the Original Article "Intensive Blood-Pressure Control in Patients with Previous Ischemic Stroke.” The trial name, OPTIMAL-STROKE, is in parentheses after the title. The graph shows the cumulative hazard of the primary outcome. The trial results are being presented at the American Heart Association Scientific Sessions 2026. The logo of the New England Journal of Medicine is at the bottom.

ALT This image is a slide detailing information from a study titled "OPTIMAL-STROKE: Intensive Blood-Pressure Control in Patients with Previous Ischemic Stroke." The slide includes the objective, study design, and conclusions. The study aims to investigate intensive blood pressure control's effect on cardiovascular risk after cerebrovascular events, with a design of an open-label, randomized study involving 4,368 participants. Results suggest that targeting a systolic BP of less than 120 mm Hg lowers the incidence of major cardiovascular events compared to 140 mm Hg in patients with previous ischemic stroke or transient ischemic attack. The logo of the American Heart Association is in the bottom left corner.

ALT This image is a slide from a presentation by the American Heart Association. It is titled "OCEANIC-STROKE," focusing on Factor XIa inhibition by Asundexian in patients with recent non-cardioembolic ischemic stroke (NCIS) or high-risk transient ischemic attack (TIA). The slide outlines the study's objective, design, and conclusions. The background is red and white with the association's logo in the bottom left corner.

ALT A graph from the Original Article " Pelacarsen and Cardiovascular Outcomes in Patients with High Lipoprotein(a).” The trial name, Lp(a)HORIZON, is in parentheses after the title. The graph shows four-component MACE in full population with lipoprotein(a) level 70 mg/dl. The trial results are being presented at the American Heart Association Scientific Sessions 2026. The logo of the New England Journal of Medicine is at the bottom.

ALT This image is a presentation slide from the American Heart Association, titled "ZEUS: Interleukin-6 Inhibition with Ziltivekimab for Atherosclerotic Disease." It summarizes a study on the effects of ziltivekimab on cardiovascular events in patients with atherosclerotic cardiovascular disease (ASCVD), chronic kidney disease (CKD), and cardiovascular inflammation. The study involved 6,376 participants and found that lowering interleukin-6 levels with ziltivekimab did not reduce the risk of cardiovascular events compared to placebo. The slide includes the American Heart Association logo.

ALT This image is a slide presentation titled "Lp(a) HORIZON: Pelacarsen and Cardiovascular Outcomes in Patients with High Lipoprotein(a)." It details an objective to evaluate pelacarsen's effectiveness in reducing major cardiovascular events in patients with high lipoprotein(a). The study is described as a Phase 3, international, double-blind, randomized, placebo-controlled trial with 8,322 participants. Results indicate that pelacarsen lowered lipoprotein(a) but did not reduce major adverse cardiovascular events compared to a placebo. The American Heart Association logo is present at the bottom left.
















